AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18041488 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 6 mg
Number of subjects: 67
Study 18041488 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 1 mg
Number of subjects: 67
Study 18041488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 15506578 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnoses for inhalational anthrax
Number of subjects: 665
Study 15506578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal cases of inhalational anthrax
Number of subjects: 665
Study 11467270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (risk factor checklist and training video)
Number of subjects: 50
Study 11467270 — intervention group
Group type: COMPARATOR
Intervention: One intervention (either checklist or training video)
Number of subjects: 50
Study 11467270 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 50
Study 9733365 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.4 mg/day; 1 month)
Number of subjects: 0
Study 9733365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9733365 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 0
Study 8056186 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 18
Study 8056186 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (CT)
Number of subjects: 18
Study 8056186 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 18
Study 2498619 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone vaginal rings releasing 7 micrograms/24 h of 17 beta‐oestradiol (E2)
Number of subjects: 2
Study 790888 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 1%
Number of subjects: 45
Study 790888 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine 1%
Number of subjects: 45
Study 31541517 — intervention group
Group type: EXPERIMENTAL
Intervention: Short MDIs (6 or 8 mm long)
Number of subjects: 63
Study 31541517 — intervention group
Group type: COMPARATOR
Intervention: Standard MDIs (10-14 mm long)
Number of subjects: 63
Study 29726939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 6 mg/kg
Number of subjects: 1756
Study 29726939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 130 mg
Number of subjects: 1756
Study 29726939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1756
Study 29726939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 12 weeks (q12w)
Number of subjects: 1756
Study 29726939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 8 weeks (q8w)
Number of subjects: 1756
Study 29726939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (all doses)
Number of subjects: 1756
Study 27266771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural psychotherapy
Number of subjects: 60
Study 27266771 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 60
Study 27266771 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 60
Study 24884910 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidas intervention
Number of subjects: 89
Study 24884910 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 89
Study 22840987 — intervention group
Group type: EXPERIMENTAL
Intervention: PRGF-Endoret
Number of subjects: 176
Study 22840987 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA)
Number of subjects: 176
Study 19725852 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography to evaluate myocardial viability before CRT implantation
Number of subjects: 51
Study 19725852 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of MR in patients with acute response
Number of subjects: 51
Study 19725852 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MR presence and viability in the region of the pacing lead
Number of subjects: 51
Study 19725852 — intervention group
Group type: EXPERIMENTAL
Intervention: Viability in the region of the pacing lead
Number of subjects: 51
Study 19725852 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of MR
Number of subjects: 51
Study 18727339 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm compresses applied to the injection site before self-injection
Number of subjects: 50
Study 18727339 — intervention group
Group type: COMPARATOR
Intervention: Usual methods of injection preparation
Number of subjects: 50
Study 15715686 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 injections
Number of subjects: 140
Study 15715686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 12870422 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Disorder Inventory (EDI-2)
Number of subjects: 2
Study 12870422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cronbach's alpha for EDI-2 subscales
Number of subjects: 2
Study 10929907 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallstone recurrence patients
Number of subjects: 33
Study 10929907 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without gallstone recurrence
Number of subjects: 33
Study 10929907 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study 8672354 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid priming (2.4% modified fluid gelatin, n = 10)
Number of subjects: 20
Study 8672354 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid priming (n = 10)
Number of subjects: 20
Study 1891561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessment post coronary artery bypass surgery
Number of subjects: 104
Study 6299982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline subcutaneously
Number of subjects: 14
Study 6299982 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg terbutaline orally
Number of subjects: 14
Study 6299982 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 14
Study 31864383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool Kids Anxiety Program - Social Enhanced (CK-E)
Number of subjects: 96
Study 31864383 — intervention group
Group type: COMPARATOR
Intervention: Generic G-CBT program for anxiety disorders
Number of subjects: 96
Study 29310899 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg plus Rilpivirine 25 mg
Number of subjects: 1028
Study 29310899 — intervention group
Group type: COMPARATOR
Intervention: Current ART regimen (CAR)
Number of subjects: 1028
Study 23754205 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole gel (3% w/v)
Number of subjects: 20
Study 23754205 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole solution (0.5% w/v)
Number of subjects: 20
Study 22226343 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 5 mg
Number of subjects: 0
Study 22226343 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 10 mg
Number of subjects: 0
Study 22226343 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 5 mg (bipolar disorder)
Number of subjects: 0
Study 22226343 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 10 mg (bipolar disorder)
Number of subjects: 0
Study 22226343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20145598 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0
Study 20145598 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 20145598 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 0
Study 16616147 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800 mg/day
Number of subjects: 81
Study 16616147 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 15923251 — intervention group
Group type: EXPERIMENTAL
Intervention: WLB+AFB
Number of subjects: 1173
Study 15923251 — intervention group
Group type: COMPARATOR
Intervention: WLB
Number of subjects: 1173
Study 12405366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal drug therapy (IDT)
Number of subjects: 67
Study 12405366 — intervention group
Group type: COMPARATOR
Intervention: Conventional pain therapy (CPT)
Number of subjects: 67
Study 10211272 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured teaching technique (the silent run through)
Number of subjects: 0
Study 10211272 — intervention group
Group type: COMPARATOR
Intervention: Control group (students taught at another hospital)
Number of subjects: 0
Study 7840079 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin supplementation (10 mg/d)
Number of subjects: 22
Study 7840079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2965140 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol (0.75 micrograms/kg)
Number of subjects: 12
Study 2965140 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol (1.5 micrograms/kg)
Number of subjects: 12
Study 2965140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29996800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5 g daily in two divided doses
Number of subjects: 42
Study 29996800 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) given intravenously as a monthly pulse
Number of subjects: 42
Study 27804272 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 153
Study 27804272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 24147994 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed drilling/piezoelectric osteotomy (test group)
Number of subjects: 15
Study 24147994 — intervention group
Group type: COMPARATOR
Intervention: Conventional drilling (control group)
Number of subjects: 15
Study 24147994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 22130403 — intervention group
Group type: EXPERIMENTAL
Intervention: Front Crawl (FC)
Number of subjects: 11
Study 22130403 — intervention group
Group type: EXPERIMENTAL
Intervention: Backstroke (BK)
Number of subjects: 11
Study 22130403 — intervention group
Group type: EXPERIMENTAL
Intervention: Breaststroke (BR)
Number of subjects: 11
Study 22130403 — intervention group
Group type: EXPERIMENTAL
Intervention: Butterfly (FLY)
Number of subjects: 11
Study 20442386 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg for weight 18-35.9 kg or 500 mg for weight >= 36 kg) 3 days per week for 168 days
Number of subjects: 260
Study 20442386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 20442386 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 260
Study 18403672 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg qd) plus Formoterol (12 microg bid)
Number of subjects: 605
Study 18403672 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 microg bid) plus Fluticasone (500 microg bid)
Number of subjects: 605
Study 19406291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (daily oral doses starting at 25mg, increasing to therapeutic levels up to 200mg)
Number of subjects: 52
Study 19406291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 19406291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline and Placebo (both groups)
Number of subjects: 52
Study 16586190 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg to 3,600 mg)
Number of subjects: 24
Study 16586190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11311964 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (80-240 mg)
Number of subjects: 9
Study 11311964 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5-15 mg)
Number of subjects: 9
Study 11311964 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 9
Study 8985076 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regional/general anesthesia with intraoperative epidural catheter anesthesia using Bupivacaine and postoperative epidural morphine
Number of subjects: 39
Study 8985076 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with postoperative patient-controlled intravenous morphine
Number of subjects: 39
Study 8985076 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (epidural and general anesthesia)
Number of subjects: 39
Study 8985076 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with operative times greater than 5 hours
Number of subjects: 39
Study 8501777 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (1.2 l. per day, containing 60 mEq. potassium and 190 mEq. citrate)
Number of subjects: 11
Study 8501777 — intervention group
Group type: COMPARATOR
Intervention: Potassium citrate (60 mEq. per day)
Number of subjects: 11
Study 3630312 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual nifedipine 20 mg
Number of subjects: 25
Study 3630312 — intervention group
Group type: EXPERIMENTAL
Intervention: intravenous nifedipine 1 mg
Number of subjects: 25
Study 3630312 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 11775718 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement Group Postvention (BGP)
Number of subjects: 60
Study 11775718 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Group Postvention (SGP)
Number of subjects: 60
Study 11775718 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined BGP and SGP
Number of subjects: 60
Study 30611715 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducative intervention (25-min session)
Number of subjects: 352
Study 30611715 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 352
Study 29161549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided caudal block (Group U, n=68)
Number of subjects: 134
Study 29161549 — intervention group
Group type: COMPARATOR
Intervention: Conventional caudal block (Group C, n=66)
Number of subjects: 134
Study 27233239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg infusion over 10 min, followed by 2 mg/kg if AF not terminated)
Number of subjects: 217
Study 27233239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 27233239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 217
Study 25280032 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod treatment for 30 days
Number of subjects: 157
Study 25280032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 157
Study 22371457 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video games
Number of subjects: 0
Study 22371457 — intervention group
Group type: COMPARATOR
Intervention: Inactive video games
Number of subjects: 0
Study 19775705 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized internal thoracic artery harvesting
Number of subjects: 41
Study 19775705 — intervention group
Group type: COMPARATOR
Intervention: Pedicled internal thoracic artery harvesting
Number of subjects: 41
Study 17369518 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) combined with task-specific upper extremity rehabilitation
Number of subjects: 15
Study 17369518 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving task-specific therapy alone
Number of subjects: 15
Study 14982768 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole with Mylanta under fasting conditions
Number of subjects: 12
Study 14982768 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole with Mylanta under nonfasting conditions
Number of subjects: 12
Study 14982768 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole with high-fat breakfast
Number of subjects: 12
Study 14982768 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole alone under fasting conditions
Number of subjects: 12
Study 14982768 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole alone under nonfasting conditions
Number of subjects: 12
Study 12003471 — intervention group
Group type: EXPERIMENTAL
Intervention: High threat condition
Number of subjects: 0
Study 12003471 — intervention group
Group type: COMPARATOR
Intervention: Low threat condition
Number of subjects: 0
Study 9988543 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen receptor status positive
Number of subjects: 0
Study 9988543 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone receptor status positive
Number of subjects: 0
Study 7859244 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10 mg QD to 20 mg QD, titrated based on blood pressure response)
Number of subjects: 3742
Study 7859244 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (part of antihypertensive regimen)
Number of subjects: 3742
Study 7859244 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 3742
Study 2814211 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 29
Study 2814211 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 29
Study 30895321 — intervention group
Group type: EXPERIMENTAL
Intervention: E+/E+ (ergot alkaloid exposure during both MID and LATE gestation)
Number of subjects: 36
Study 30895321 — intervention group
Group type: EXPERIMENTAL
Intervention: E-/E+ (ergot alkaloid exposure switched from E- to E+ during LATE gestation)
Number of subjects: 36
Study 30895321 — intervention group
Group type: EXPERIMENTAL
Intervention: E+/E- (ergot alkaloid exposure only during MID gestation)
Number of subjects: 36
Study 30895321 — intervention group
Group type: EXPERIMENTAL
Intervention: E+ (ergot alkaloid exposure during LATE gestation)
Number of subjects: 36
Study 28879792 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg)
Number of subjects: 0
Study 28879792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26245919 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding nitinol stenting
Number of subjects: 92
Study 26245919 — intervention group
Group type: COMPARATOR
Intervention: PTA with bailout stenting
Number of subjects: 92
Study 23481908 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with pre‐determined optimal AVD
Number of subjects: 25
Study 23481908 — intervention group
Group type: COMPARATOR
Intervention: Nominal AV delay with AAI pacing
Number of subjects: 25
Study 22088520 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban with unfractionated heparin (UFH)
Number of subjects: 120
Study 22088520 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban with dalteparin
Number of subjects: 120
Study 18157558 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Isomalt solutions rinsed for 5 minutes daily
Number of subjects: 2
Study 18157558 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Isomalt additions to re- or demineralizing solutions
Number of subjects: 2
Study 18157558 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Isomalt containing toothpaste brushed three times daily
Number of subjects: 2
Study 16864741 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 7080
Study 16864741 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 7080
Study 12588772 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg (twice daily)
Number of subjects: 39
Study 12588772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 10567042 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS-No Psych group
Number of subjects: 39
Study 10567042 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS-Psych group
Number of subjects: 39
Study 10567042 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 39
Study 8720318 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg t.i.d. over 5 days)
Number of subjects: 12
Study 8720318 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg o.d. over 3 days)
Number of subjects: 12
Study 8720318 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 12
Study 1770275 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin releasing hormone agonist (GNRHa), Buserelin, prior to and during induction of ovulation by hMG (Group I‐‐long protocol)
Number of subjects: 54
Study 1770275 — intervention group
Group type: COMPARATOR
Intervention: GnRHa starting on the first day of the cycle together with induction of ovulation by hMG (Group II‐‐short protocol)
Number of subjects: 54
Study 6889803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride
Number of subjects: 40
Study 6889803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30448180 — intervention group
Group type: EXPERIMENTAL
Intervention: MiSight® contact lenses (CLs)
Number of subjects: 74
Study 30448180 — intervention group
Group type: COMPARATOR
Intervention: Single vision spectacles (SV)
Number of subjects: 74
Study 28008174 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront autologous transplant (ASCT)
Number of subjects: 529
Study 26633163 — intervention group
Group type: EXPERIMENTAL
Intervention: Top tertile of dietary glycemic index (GI)
Number of subjects: 4010
Study 26633163 — intervention group
Group type: EXPERIMENTAL
Intervention: Top tertile of dietary glycemic load (GL)
Number of subjects: 4010
Study 26633163 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures of dietary GI/GL
Number of subjects: 4010
Study 26633163 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with obesity or diabetes
Number of subjects: 4010
Study 25148839 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, multimodal exercise intervention (cardiorespiratory, flexibility, balance, and muscular strength training) 3 days per week for 3 months
Number of subjects: 319
Study 25148839 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, multimodal exercise intervention
Number of subjects: 319
Study 21798872 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated antenatal corticosteroids
Number of subjects: 145
Study 21798872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145